Drug Interactions of Sitagliptin with Anti-retroviral Drugs in Animals. Pharmacodynamic and Pharmacokinetic Interactions of SItagliptin in rats and rabbits

      Аннотация: Polypharmacy is very common practice for the patients suffering from chronic diseases and thus leads to the undesirable potential drug-drug interactions (pharmacodynamic or pharmacokinetic) which can alter safety and efficacy profile of a drug in many ways. Recent reports reveal that drug-drug interactions play a vital role in reported adverse events and the majority of drugs are withdrawn for safety reasons from the US market are related to significant drug-drug interactions. In the light of this perspective, there is need to focus on the evaluation of possible drug-drug interactions associated with polypharmacy and drugs used in the treatment of chronic diseases. Diabetes mellitus prevalence was 4.6 times higher and diabetes mellitus incidence was 4.1 times higher in HIV- infected men than in HIV- seronegative persons. HIV infected people are at increased risk of developing diabetes mellitus. Thus with increasing co-incidence of diabetes and HIV infected patients, the coadministration of antidiabetic drugs with antiretroviral drugs becomes essential. The present study was taken up to evaluate the influence of selected antiretroviral drugs.

Ключевые слова: animal models, drug interactions, efavirenz, Pharmacodynamic, pharmacokinetic, Sitagliptin, Raltegravir, Emitricitabine